Newswire and Healthcare Information

Iselin NJ, May 19, 2006 Pharmos Corporation (Nasdaq: PARS), which recently entered into a definitive agreement to acquire Vela Pharmaceuticals Inc. (Vela), announced today that it has retained Burrill & Company on several business development initiatives. Burrill & Company is a life sciences merchant bank headquartered in San Francisco. Pharmos said that Burrill will explore out-licensing opportunities for several of Pharmos’ assets. Burrill’s efforts will […]

Iselin NJ, May 11, 2006 Pharmos Corporation (Nasdaq: PARS), which recently entered into a definitive agreement to acquire (subject to stockholder approval and other closing conditions) Vela Pharmaceuticals Inc., announced today that it will present at the Rodman & Renshaw Third Annual Healthcare Conference on Monday, May 15, 2006 at 10:05 AM Eastern Time. Haim Aviv, PH.D., Chairman & CEO, will provide an update on […]

Highlights Pending Acquisition of Vela Pharmaceuticals Iselin NJ, May 9, 2006 Pharmos Corporation (Nasdaq: PARS) today reported results for the first quarter ended March 31, 2006. A major development of the quarter included the previously announced agreement to acquire Vela Pharmaceuticals Inc., a venture-capital backed, privately owned company specializing in the development of medicines related to diseases of the nervous system including disorders of the […]

Iselin NJ, April 10, 2006 – Pharmos Corporation (Nasdaq: PARS) today announced it has been awarded a grant of up to US$ 1.3 million by the Office of the Chief Scientist (OCS) of Israel’s Ministry of Industry and Trade. The funds have been granted for the development of drug candidates from the Company’s CB2-selective platform of synthetic cannabinoids. Approximately 50% of the funding is designated for […]

Company Will Seek to Develop, Partner, or Outlicense Vela Assets Iselin NJ, April 5, 2006 Pharmos Corporation (Nasdaq: PARS), which recently entered into a definitive agreement to acquire (subject to stockholder approval and other closing conditions) Vela Pharmaceuticals Inc. (Vela), has set strategic priorities for the proposed development of Vela’s later-stage assets. These assets include dextofisopam (also previously known as R-tofisopam) and tianeptine for the […]

Iselin NJ, March 17, 2006 – Pharmos Corporation (Nasdaq: PARS) announced today that United States Congressman Mike Ferguson (R-NJ) will visit Pharmos headquarters in Iselin, N.J. on Friday morning, March 17, 2006. Pharmos’ Iselin offices are located in Congressman Ferguson’s 7th Congressional District. The Congressman plans to tour Pharmos’ facility and meet Company employees. Congressman Ferguson is currently serving his third term in office since being […]

In connection with its proposed acquisition of Vela Pharmaceuticals Inc., Pharmos has filed a preliminary proxy statement and other relevant materials, and will be filing additional relevant materials in the near future, with the Securities and Exchange Commission (SEC) relating to a special meeting of shareholders. Investors and security holders of Pharmos are urged to read these documents because they contain important information about Pharmos, […]

Iselin NJ, March 15, 2006 – Pharmos Corporation (Nasdaq: PARS) today reported financial results for the fourth quarter and twelve month period ended December 31, 2005. For the fourth quarter ended December 31, 2005, Pharmos reported a net loss of $3.0 million, or $0.16 per share compared to a net loss of $4.8 million, or $0.25 per share for the same period in 2004. Total operating […]

Phase IIa Planned for Second Quarter 2006 Iselin NJ, January 26, 2006 – Pharmos Corporation (Nasdaq: PARS) announced today the Company has successfully completed a Phase I trial for cannabinor, a CB2-selective synthetic cannabinoid drug candidate that has been shown to have activity in preclinical animal models of various types of pain and several autoimmune diseases. The data indicate that cannabinor was safe and well tolerated […]

Alan Rubino Appointed President and Chief Operating Officer   Iselin NJ, November 7, 2005 – Pharmos Corporation (Nasdaq: PARS) announced today that it has appointed Alan L. Rubino President and Chief Operating Officer. Mr. Rubino replaces Gad Riesenfeld, Ph.D., who will remain at the Company in a consulting role to ensure a smooth transition. Mr. Rubino is a highly experienced 24-year veteran of Hoffmann-LaRoche where he […]